| Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m mutation … A Hata, N Katakami, H Yoshioka, J Takeshita, K Tanaka, S Nanjo, S Fujita, ... Cancer 119 (24), 4325-4332, 2013 | 196 | 2013 |
| Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non–small-cell lung cancer after acquired resistance to EGFR-TKI A Hata, N Katakami, H Yoshioka, R Kaji, K Masago, S Fujita, Y Imai, ... Journal of thoracic oncology 10 (11), 1553-1559, 2015 | 166 | 2015 |
| Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer Y Togashi, K Masago, M Fukudo, T Terada, S Fujita, K Irisa, Y Sakamori, ... Journal of Thoracic Oncology 5 (7), 950-955, 2010 | 156 | 2010 |
| CT-guided fine-needle aspiration and core needle biopsies of pulmonary lesions: a single-center experience with 750 biopsies in Japan J Takeshita, K Masago, R Kato, A Hata, R Kaji, S Fujita, N Katakami American Journal of Roentgenology 204 (1), 29-34, 2015 | 134 | 2015 |
| Transformation to SCLC after treatment with the ALK inhibitor alectinib S Fujita, K Masago, N Katakami, Y Yatabe Journal of Thoracic Oncology 11 (6), e67-e72, 2016 | 127 | 2016 |
| Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer A Hata, H Yoshioka, S Fujita, K Kunimasa, R Kaji, Y Imai, K Tomii, ... Journal of Thoracic Oncology 5 (10), 1524-1528, 2010 | 101 | 2010 |
| Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer T Kato, N Masuda, Y Nakanishi, M Takahashi, T Hida, H Sakai, S Atagi, ... Lung cancer 104, 111-118, 2017 | 98 | 2017 |
| Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa, S Nanjo, K Otsuka, ... Lung cancer 74 (2), 268-273, 2011 | 86 | 2011 |
| All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system C Tabata, H Kubo, R Tabata, M Wada, K Sakuma, M Ichikawa, S Fujita, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 290 (3 …, 2006 | 83 | 2006 |
| Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma A Hata, N Katakami, S Fujita, R Kaji, Y Imai, Y Takahashi, T Nishimura, ... Journal of thoracic oncology 5 (8), 1197-1200, 2010 | 80 | 2010 |
| How sensitive are epidermal growth factor receptor–tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene–sensitive mutations? A Hata, N Katakami, H Yoshioka, K Kunimasa, S Fujita, R Kaji, ... Journal of Thoracic Oncology 8 (1), 89-95, 2013 | 78 | 2013 |
| High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs T Kawamura, A Hata, J Takeshita, S Fujita, M Hayashi, K Tomii, ... Cancer Chemotherapy and Pharmacology 75, 1261-1266, 2015 | 74 | 2015 |
| Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer M Nishio, T Hida, S Atagi, H Sakai, K Nakagawa, T Takahashi, N Nogami, ... ESMO open 2, e000108, 2017 | 72 | 2017 |
| Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma K Masago, R Asato, S Fujita, S Hirano, Y Tamura, T Kanda, T Mio, ... International journal of cancer 124 (11), 2744-2749, 2009 | 65 | 2009 |
| Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC> ATC in exon 20 … K Masago, S Fujita, K Irisa, YH Kim, M Ichikawa, T Mio, M Mishima Japanese journal of clinical oncology 40 (11), 1105-1109, 2010 | 64 | 2010 |
| Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer T Hida, M Nishio, N Nogami, Y Ohe, H Nokihara, H Sakai, M Satouchi, ... Cancer science 108 (5), 1000-1006, 2017 | 63 | 2017 |
| High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer A Hata, R Kaji, S Fujita, N Katakami Journal of Thoracic Oncology 6 (3), 653-654, 2011 | 63 | 2011 |
| EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage III adenocarcinoma K Tanaka, T Hida, Y Oya, T Oguri, T Yoshida, J Shimizu, Y Horio, A Hata, ... Journal of Thoracic Oncology 10 (12), 1720-1725, 2015 | 59 | 2015 |
| Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non‑squamous non-small‑cell lung cancer K Masago, D Fujimoto, S Fujita, A Hata, R Kaji, K Ohtsuka, C Okuda, ... Molecular and Clinical Oncology 3 (2), 415-419, 2015 | 56 | 2015 |
| Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis Y Togashi, K Masago, M Fukudo, T Terada, Y Ikemi, YH Kim, S Fujita, ... Journal of Thoracic Oncology 5 (5), 601-605, 2010 | 56 | 2010 |
